Thank you, Mr. Chairman.
I'd like to thank the witnesses for joining us.
As you know, last week we met with industry officials as part of the review process. One sticking point seems to be the wait times under the program for recommending that certain pharmaceuticals be listed.
I listened closely to your opening remarks, Ms. Bruce, and I came to the conclusion that even if faster decisions were made on new listings under the program, your respective departments wouldn't be able to act any quicker on this and new drugs would not be available any faster.
Is my understanding of the situation correct?